Rhythm Pharmaceuticals (RYTM)
NASDAQ:RYTM
Want to see RYTM full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.81Last Year’s EPS
-0.75Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and regulatory picture: sequential revenue growth (5%), strong international acceleration (27% QoQ outside U.S.), an encouraging early HO launch (150+ start forms, broad prescriber base), EU marketing authorization and a progressing Japan filing, supported by a solid cash runway (~$341M). Offsetting these positives are meaningful increases in operating expenses (notably SG&A up ~62.7% YoY), ongoing GAAP losses (Q1 EPS -$0.83) and near-term variability and uncertainty tied to payer policy timing, inventory effects and the pace of clinical-to-commercial conversions. Overall, the operational momentum and regulatory wins outweigh the financial and execution risks highlighted for the near term.Company Guidance
Quarterly Revenue Growth
Global net revenues of $60.1M in Q1 2026, representing 5% sequential growth from $57M in Q4 2025. 61% of Q1 revenue was generated in the United States.
International Revenue Acceleration
Revenue outside the U.S. rose from $18.3M to $23.2M in Q1, a 27% sequential increase driven by higher sales volumes in Germany and France and named-patient markets (e.g., Saudi Arabia, Greece).
Growth in Patients on Reimbursed Therapy
Globally, patients on reimbursed therapy increased by 8% quarter-over-quarter, driven primarily by BBS and international early access programs.
Strong Early Launch for Acquired Hypothalamic Obesity (HO)
More than 150 start forms received in the first six weeks post-U.S. approval (approx. 40 from clinical trial conversions). ~110 unique prescribers (≈80% new to IMCIVREE) and ~80% of prescribers are endocrinologists. U.S. salesforce scaled from 16 to 42 reps to address an estimated ~10,000-patient HO opportunity in the U.S. and Europe.
Regulatory and Market Access Milestones
FDA approval for acquired HO (March 19, 2026), European Commission marketing authorization granted quickly following positive CHMP opinion, and PMDA in Japan has accepted the NDA with anticipated approval/launch in Japan by end of 2026 and EU country launches targeted in 2027.
Real-World Evidence and Early Access Programs
Early access programs in France and Italy provided meaningful reimbursed patient experience; French AP1 program produced real-world data from >60 HO patients (including up to 12 months on therapy) to be presented at European Congress of Endocrinology.
Solid Cash Position and Runway
Ended Q1 with approximately $341M in cash, cash equivalents and short-term investments, projected to fund planned operations for at least 24 months.
Pipeline and Milestones on Track
Near-term clinical and program milestones: anticipated sharing of Dr. Miller's 6-month PWS data at Endo (June), RM-718/718 data midyear, Part C HO results targeted for Q2 call, and CMC/bioequivalence work underway aiming for a Phase III start of bivamelagon (RM-718) in HO by end of 2026.
RYTM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RYTM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $85.58 | $92.31 | +7.86% |
Feb 26, 2026 | $99.15 | $98.07 | -1.09% |
Nov 04, 2025 | $113.74 | $104.99 | -7.69% |
Aug 05, 2025 | $90.24 | $88.57 | -1.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rhythm Pharmaceuticals (RYTM) report earnings?
Rhythm Pharmaceuticals (RYTM) is schdueled to report earning on Aug 04, 2026, TBA (Confirmed).
What is Rhythm Pharmaceuticals (RYTM) earnings time?
Rhythm Pharmaceuticals (RYTM) earnings time is at Aug 04, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RYTM EPS forecast?
RYTM EPS forecast for the fiscal quarter 2026 (Q2) is -0.81.